Cargando…

Virtual screening and molecular dynamics simulations provide insight into repurposing drugs against SARS-CoV-2 variants Spike protein/ACE2 interface

After over two years of living with Covid-19 and hundreds of million cases worldwide there is still an unmet need to find proper treatments for the novel coronavirus, due also to the rapid mutation of its genome. In this context, a drug repositioning study has been performed, using in silico tools t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pirolli, Davide, Righino, Benedetta, Camponeschi, Chiara, Ria, Francesco, Di Sante, Gabriele, De Rosa, Maria Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880937/ https://www.ncbi.nlm.nih.gov/pubmed/36707679 http://dx.doi.org/10.1038/s41598-023-28716-8

Ejemplares similares

Publisher Correction: Virtual screening and molecular dynamics simulations provide insight into repurposing drugs against SARS-CoV-2 variants Spike protein/ACE2 interface
por: Pirolli, Davide, et al.
Publicado: (2023)

Prediction of CD44 Structure by Deep Learning-Based Protein Modeling
por: Camponeschi, Chiara, et al.
Publicado: (2023)

A TLR/CD44 axis regulates T cell trafficking in experimental and human multiple sclerosis
por: Tredicine, Maria, et al.
Publicado: (2022)

Identification and Modeling of a GT-A Fold in the α-Dystroglycan Glycosylating Enzyme LARGE1
por: Righino, Benedetta, et al.
Publicado: (2020)

Identification and antitumor activity of a novel inhibitor of the NIMA-related kinase NEK6
por: De Donato, Marta, et al.
Publicado: (2018)

A Repurposed Drug Screen Identifies Compounds That Inhibit the Binding of the COVID-19 Spike Protein to ACE2
por: Tsegay, Kaleb B., et al.
Publicado: (2021)

Non-synonymous variation and protein structure of candidate genes associated with selection in farm and wild populations of turbot (Scophthalmus maximus)
por: Andersen, Øivind, et al.
Publicado: (2023)

The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition
por: Hattori, Takamitsu, et al.
Publicado: (2020)

The ACE2-binding Interface of SARS-CoV-2 Spike Inherently Deflects Immune Recognition
por: Hattori, Takamitsu, et al.
Publicado: (2021)

Computational search for drug repurposing to identify potential inhibitors against SARS-COV-2 using Molecular Docking, QTAIM and IQA methods in viral Spike protein – Human ACE2 interface
por: Faria, Sergio H.D.M., et al.
Publicado: (2021)

Repurposing Astragalus Polysaccharide PG2 for Inhibiting ACE2 and SARS-CoV-2 Spike Syncytial Formation and Anti-Inflammatory Effects
por: Lee, Chia-Yin, et al.
Publicado: (2023)

Zn(2+) and Cu(2+) Interaction with the Recognition Interface of ACE2 for SARS-CoV-2 Spike Protein
por: Pelucelli, Alessio, et al.
Publicado: (2023)

Novel Polymyxin-Inspired Peptidomimetics Targeting the SARS-CoV-2 Spike:hACE2 Interface
por: Bugatti, Kelly, et al.
Publicado: (2023)

Differences in the organization of interface residues tunes the stability of the SARS-CoV-2 spike-ACE2 complex
por: Miotto, Mattia, et al.
Publicado: (2023)

Modeling the Ternary Complex TCR-Vβ/CollagenII(261–273)/HLA-DR4 Associated with Rheumatoid Arthritis
por: De Rosa, Maria Cristina, et al.
Publicado: (2010)

Cervids ACE2 Residues that Bind the Spike Protein can Provide Susceptibility to SARS-CoV-2
por: Lopes, Luciano Rodrigo
Publicado: (2023)

Missense variants in human ACE2 strongly affect binding to SARS-CoV-2 Spike providing a mechanism for ACE2 mediated genetic risk in Covid-19: A case study in affinity predictions of interface variants
por: MacGowan, Stuart A., et al.
Publicado: (2022)

Dynamics of the ACE2–SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms
por: Ali, Amanat, et al.
Publicado: (2020)

In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19
por: BR, Bharath, et al.
Publicado: (2020)

Spike residue 403 affects binding of coronavirus spikes to human ACE2
por: Zech, Fabian, et al.
Publicado: (2021)

Immunopathology of SARS-CoV-2 Infection: A Focus on T Regulatory and B Cell Responses in Children Compared with Adults
por: Di Sante, Gabriele, et al.
Publicado: (2022)

Molecular docking simulation reveals ACE2 polymorphisms that may increase the affinity of ACE2 with the SARS-CoV-2 Spike protein
por: Calcagnile, Matteo, et al.
Publicado: (2021)

Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
por: Gurung, Arun Bahadur, et al.
Publicado: (2021)

The Development of Pharmacophore Models for the Search of New Natural Inhibitors of SARS-CoV-2 Spike RBD–ACE2 Binding Interface
por: Semenov, Valentin A., et al.
Publicado: (2022)

Targeting the Spike: Repurposing Mithramycin and Dihydroergotamine to Block SARS-CoV-2 Infection
por: Stagnoli, Soledad, et al.
Publicado: (2023)

The Repurposed ACE2 Inhibitors: SARS-CoV-2 Entry Blockers of Covid-19
por: Ahmad, Iqrar, et al.
Publicado: (2021)

A Drug Repurposing Approach for Antimalarials Interfering with SARS-CoV-2 Spike Protein Receptor Binding Domain (RBD) and Human Angiotensin-Converting Enzyme 2 (ACE2)
por: Coghi, Paolo, et al.
Publicado: (2021)

Recovering or Persisting: The Immunopathological Features of SARS-CoV-2 Infection in Children
por: Buonsenso, Danilo, et al.
Publicado: (2022)

Cortical Spiking Network Interfaced with Virtual Musculoskeletal Arm and Robotic Arm
por: Dura-Bernal, Salvador, et al.
Publicado: (2015)

Virtual Screening of Repurposed Drugs as Potential Spike Protein Inhibitors of Different SARS-CoV-2 Variants: Molecular Docking Study
por: Eweas, Ahmad F., et al.
Publicado: (2022)

Molecular dynamics simulations highlight the altered binding landscape at the spike-ACE2 interface between the Delta and Omicron variants compared to the SARS-CoV-2 original strain
por: Pitsillou, Eleni, et al.
Publicado: (2022)

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis
por: Alexpandi, Rajaiah, et al.
Publicado: (2020)

Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2)
por: Egieyeh, Samuel, et al.
Publicado: (2021)

Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates
por: Alazmi, Meshari, et al.
Publicado: (2020)

SARS-CoV-2 spike and ACE2 entanglement-like binding
por: Pregnolato, Massimo, et al.
Publicado: (2023)

Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces
por: Lapaillerie, Delphine, et al.
Publicado: (2022)

S100B Protein as a Therapeutic Target in Multiple Sclerosis: The S100B Inhibitor Arundic Acid Protects from Chronic Experimental Autoimmune Encephalomyelitis
por: Camponeschi, Chiara, et al.
Publicado: (2021)

Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection
por: Wang, Jingfang, et al.
Publicado: (2020)

Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection
por: Luan, Junwen, et al.
Publicado: (2020)

Can polyoxometalates (POMs) prevent of coronavirus 2019-nCoV cell entry? Interaction of POMs with TMPRSS2 and spike receptor domain complexed with ACE2 (ACE2-RBD): Virtual screening approaches
por: Shahabadi, Nahid, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_l9rj7maua1bo7c9uk44n2vqt52